Solexa Granted European Patent on use of Single Molecules for Sequencing
News Feb 02, 2006
Solexa, Inc. has announced that the European Patent Office has granted the company a key patent covering the use of single molecules for DNA analysis.
This granted patent, EP1105529B1, further strengthens Solexa’s intellectual property (IP) portfolio, which consists of some of the earliest and fundamental patents and applications addressing the use of both single molecules and amplified colonies of single molecules for genetic analysis applications, including DNA sequencing and gene expression analysis.
"The granting of this patent reinforces Solexa’s leadership position in the field of single molecule DNA analysis," stated John West, chief executive officer of Solexa.
"While today we are focused on commercializing our Clonal Single Molecule Array™ technology, our growing IP estate around the use of single molecules for DNA analysis provides us with the core technologies to develop and commercialize a system based on non-amplified single molecules."
"Additionally, we are positioned to protect our technology assets and to enter into strategic licensing in non-competitive fields."
EP1105529B1 covers devices comprising arrays of single molecules, including polynucleotides; methods for producing the devices; and their subsequent use.
An example would be in DNA sequencing and analysis. The patent claims cover any device where fluorophores are detected using optical microscopy by virtue of being attached to planar surfaces as single discrete entities.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.